[ad_1]
Kirill Dmitryev, director of the Russian Direct Investment Fund (RTIF), which finances the Sputnik V program, said in a statement that his organization had secured “agreements with companies from Italy, Spain, France and Germany to start production of Sputnik V” . .
According to Dmitrijev, these agreements will allow the supply of the Russian vaccine to the European market “once it is authorized by the European Medicines Agency (EMA)”.
Earlier this month, the Amsterdam-based EVA launched a follow-up review of Sputnik V, an important step in approving the first non-Western product for use in the 27-nation bloc.
However, several EU countries have already started to distribute it.
Hungary approved Sputnik V in February and began using it in its vaccination campaign. The Czech Republic and Slovakia also ordered the drug and said they would not wait for EVA approval.
According to the developers, Sputnik V has been registered in more than 50 countries.
Russia certified the drug in August last year, which has yet to conduct large-scale clinical trials, leading many experts to question the drug.
However, the authoritative medical journal The Lancet subsequently published research showing that the vaccine is safe and 91.6 percent effective. The third stage of clinical trials involved 20,000. volunteers.
RTIF said on Monday that 3.5 million people in Russia have received both doses of Sputnik V.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
